ASCO GI 2021 | ICONIC: FLOT-A in resectable oesophagogastric adenocarcinoma

Avani Athauda, MBBS, MRCP, The Royal Marsden NHS Foundation Trust, London, UK, presents results of an interim safety analysis of 15 patients from the ongoing ICONIC study (NCT03399071), a single-arm Phase II trial investigating the safety and efficacy of periperative FLOT in combination with avelumab, an anti-PD-L1 antibody in patients with resectable esophagogastric adenocarcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).